NEW YORK ─ DCN Dx on Thursday announced it has acquired Moorestown, New Jersey-based PortaScience, a point-of-care diagnostics company focused on dry chemistry technology.
Carlsbad, California-based DCN, a developer of lateral flow diagnostic tests, said the acquisition expands its product portfolio and point-of-care diagnostic development services.
Financial and other terms of the deal were not disclosed.
With the acquisition, PortaScience's customers will have access to expanded contract assay development services that include dry chemistry, lateral flow immunoassay, flow-through, and microfluidic formats, DCN said.
PortaScience has received 14 small business innovation research grants and commercialized and out-licensed numerous products since its founding in 1999, DCN said.
"DCN Dx was attracted to PortaScience's strong alignment of science, client relationships, and quality standards," Charlie Mamrack, CEO of DCN, said in a statement.
PortaScience's operations will remain in New Jersey.